Eli Lilly and Co. has received the Federal Drug Administration’s breakthrough therapy designation for a drug in development ...
Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough ...
Sofetabart mipitecan received FDA breakthrough therapy designation for platinum-resistant ovarian cancer after prior ...
Sofetabart mipitecan is an antibody-drug conjugate consisting of an Fc-silent, folate receptor alpha specific monoclonal antibody attached to an exatecan payload.
New study and promising results from the first clinical trial in patients provide novel insights and new hope for one of the deadliest of cancers. Gastric cancer remains a formidable adversary, ...
Zejula can now be used as a maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have completely or partially shrunk after ...
Validity of the Patient-Reported Outcome Measurement Information System (PROMIS) Sexual Interest and Satisfaction Measures in Men Following Radical Prostatectomy Compared with CRSa, CRS-HIPEC improved ...
Gastric cancers commonly spread to the peritoneum. Its presence significantly alters patient prognosis and treatment-intent; however, current methods of peritoneal staging are inaccurate. Peritoneal ...
A new wave of cancer treatments is looking promising for the future of oncologic care. The ovarian cancer drug RC88, which is made by the Chinese biopharmaceutical company RemeGen, received FDA ...
12don MSN
I Was 21 When My Doctors Told Me I Had A Year To Live. What Happened Next Left Them Stunned.
"The prognosis was so poor that the hospital called in grief counselors to speak with my family and help prepare them." ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results